Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-human evaluation of a novel sirolimus-eluting ultra-high molecular weight APTITUDE bioresorbable scaffold: 9- and 24-month imaging and clinical results of the RENASCENT II trial.
Chieffo A, Khawaja SA, Latib A, Vesga B, Moncada M, Delgado JA, Fonseca J, Testa L, Esposito G, Ferrone M, Cortese B, Maehara A, Granada JF, Colombo A; Collaborators. Chieffo A, et al. Among authors: delgado ja. EuroIntervention. 2020 Jun 12;16(2):e133-e140. doi: 10.4244/EIJ-D-19-00600. EuroIntervention. 2020. PMID: 32149709 Free article. Clinical Trial.
RENASCENT III: First in Human Evaluation of the Novel Thin Strut MAGNITUDE Sirolimus-Eluting Ultra-High Molecular Weight MAGNITUDE Bioresorbable Scaffold: 9-Month Imaging and 2-Year Clinical Results.
Ferrone M, Chieffo A, Khawaja SA, Moncada M, Colombo A, Latib A, Esposito G, Stabile E, Avvedimento M, Bedogni F, Testa L, Delgado JA, Arana C, Vesga B, Cortese B, Mahera A, Granada JF. Ferrone M, et al. Among authors: delgado ja. Circ Cardiovasc Interv. 2021 May;14(5):e010013. doi: 10.1161/CIRCINTERVENTIONS.120.010013. Epub 2021 May 18. Circ Cardiovasc Interv. 2021. PMID: 34003665 No abstract available.
First in human evaluation of the vascular biocompatibility and biomechanical performance of a novel ultra high molecular weight amorphous PLLA bioresorbable scaffold in the absence of anti-proliferative drugs: Two-year imaging results in humans.
Moncada M, Delgado JA, Colombo A, Gasior P, Ramzipoor K, Estrada A, Lee C, Dokko D, Granada JF. Moncada M, et al. Among authors: delgado ja. Catheter Cardiovasc Interv. 2018 Sep 1;92(3):E246-E253. doi: 10.1002/ccd.27444. Epub 2017 Dec 15. Catheter Cardiovasc Interv. 2018. PMID: 29243353
First in human evaluation of a novel Sirolimus-eluting ultra-high molecular weight bioresorbable scaffold: 9-, 24-and 36-months imaging and clinical results from the multi-center RENASCENT study.
Chieffo A, Khawaja SA, Vesga B, Hernandez H, Moncada M, Delgado JA, Esposito G, Ferrone M, Dager A, Arana C, Stabile E, Meliga E, De Benedictis M, Montorfano M, Latib A, Fonseca J, Gomez G, Tamburino C, Tarantini G, La Manna A, Maehara A, Granada JF, Colombo A. Chieffo A, et al. Among authors: delgado ja. Int J Cardiol. 2020 Dec 15;321:48-53. doi: 10.1016/j.ijcard.2020.08.014. Epub 2020 Aug 15. Int J Cardiol. 2020. PMID: 32810542
Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study.
Vesga B, Hernandez H, Moncada M, Gasior P, Higuera S, Dager A, Arana C, Delgado JA, Généreux P, Maehara A, Granada JF. Vesga B, et al. Among authors: delgado ja. Coron Artery Dis. 2017 Mar;28(2):126-134. doi: 10.1097/MCA.0000000000000453. Coron Artery Dis. 2017. PMID: 27879518
Safety and feasibility of robotic percutaneous coronary intervention: PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) Study.
Weisz G, Metzger DC, Caputo RP, Delgado JA, Marshall JJ, Vetrovec GW, Reisman M, Waksman R, Granada JF, Novack V, Moses JW, Carrozza JP. Weisz G, et al. Among authors: delgado ja. J Am Coll Cardiol. 2013 Apr 16;61(15):1596-600. doi: 10.1016/j.jacc.2012.12.045. J Am Coll Cardiol. 2013. PMID: 23500318 Free article. Clinical Trial.
Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.
Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C, Pocovi A, Rodriguez-Granillo AM, Schulz D, Raizner AE, Palacios I, O'Neill W, Kaluza GL, Stone G; ORAR II Investigators. Rodriguez AE, et al. J Am Coll Cardiol. 2006 Apr 18;47(8):1522-9. doi: 10.1016/j.jacc.2005.12.052. Epub 2006 Mar 29. J Am Coll Cardiol. 2006. PMID: 16630986 Free article. Clinical Trial.
124 results